Barclays
FLNA

Barclays’s Filana Therapeutics FLNA Stock Holding History

Barclays’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-20,000
Closed -$47.2K – 5519
2024
Q4 		$47.2K Hold
20,000
– – ﹤0.01% 4776
2024
Q3 		$589K Buy
+20,000
New +$461K ﹤0.01% 3681
2023
Q4 		– Sell
-141,800
Closed -$2.36M – 5333
2023
Q3 		$2.36M Buy
+141,800
New +$2.81M ﹤0.01% 1785

Other funds holding FLNA

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Barclays's FLNA Position: Q1 2026 in Review

Barclays reduced its Filana Therapeutics (FLNA) stake by 13% in Q1 2026, selling an estimated $12.5K and leaving 42,379 shares worth $71.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4173.

Barclays first reported a position in FLNA in Q2 2013 and has held it in 26 quarters since. The position peaked at $4.85M in Q4 2021. 101 funds tracked by Wall St. Rank hold FLNA as of Q1 2026.

  • Barclays held 42,379 shares of Filana Therapeutics worth $71.6K as of Q1 2026.
  • Barclays sold 6,083 Filana Therapeutics shares in Q1 2026, an estimated $12.5K.
  • Filana Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4173 holding.
  • Barclays first reported a position in Filana Therapeutics in Q2 2013 and has held it in 26 quarters since.
  • Barclays's Filana Therapeutics position peaked at $4.85M in Q4 2021.
  • 101 funds tracked by Wall St. Rank held Filana Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.